All posts by imreal

Farlong Nutraceutical Launches 90-Day Clinical Study to Determine Safety and Effectiveness of Farlong Lifeflower® Breviscapine


News Image

Farlong Lifeflower® Breviscapine

Farlong Nutraceutical is conducting a 90-day double blind, randomized, controlled, parallel study to determine the safety and effectiveness of Farlong Lifeflower® Breviscapine on improving long and short-term memory, concentration, and clarity of thinking in healthy individuals.

Farlong Nutraceutical, a vertically integrated, plant-based ingredient and supplement company, is conducting a 90-day double blind, randomized, controlled, parallel study to determine the safety and effectiveness of Farlong Lifeflower® Breviscapine on improving long and short-term memory, concentration, and clarity of thinking in healthy individuals.

Led by clinician Melanie Montgomery, Ph.D., of LifeAlyze LLC, the partially grant-funded study consists of 160 healthy individuals divided into four study groups, with the first given one placebo capsule daily, and the other three groups to receive different daily doses of Farlong Lifeflower® Breviscapine – 100 mg, 200 mg, and 400 mg each.

“We are very excited to be underway with this clinical study, as we take pride in providing consumers and practitioners with data, research and studies that showcase the effect of our products and the positive impact they can have in changing peoples’ lives,” said Jing Struve, CEO and Executive Director of Farlong Nutraceutical.

Every 30 days, subjects will be given three separate evaluations to assess their cognitive thinking, concentration, clarity of thought and general brain functions, along with having vital signs checked and bloodwork analyzed. Farlong expects the study to be completed in November with results published soon thereafter.

Lifeflower® Breviscapine is an active flavonoid component extracted from Erigeron Breviscapus, containing more than 90 percent of scutellarin. Scutellarin has been shown to enhance memory, cognitive function and brain health; increase brain circulation; and promote the development of new blood vessels. A series of safety and efficacy studies were conducted, and an expert panel committee concluded that Lifeflower® Breviscapine manufactured consistent with cGMP (Current Good Manufacturing Practice) is GRAS based on scientific procedures for use as an ingredient in yogurt, nutritional bars, smoothies at 84 mg per serving, and dietary supplements at 200 mg per person per day.

About Farlong Nutraceutical:

Farlong is a science-based and vertically integrated functional ingredient and formula provider who has more than 24 years of experience focusing on discovering, developing, and providing safe, effective, and unique medicinal herbs, plant extracts, and formulas with its own GAP (Good Agricultural Practice) certified cultivation base, cGMP (Current Good Manufacturing Practice) certified manufacturing facilities and distribution channels. Combining ancient Oriental medicine and modern technology, Farlong develops its own line of natural supplement brands, while offering contract manufacturing services and ingredients for health and beauty companies to create proprietary formulas and product lines. For more information, visit Farlong.com for supplements and 400+ ingredients, and follow on Facebook, Twitter and Instagram.

Share article on social media or email:



Why Healthcare Revenue Cycle Management Firm Prochant Continues to Rank on the Inc. 5000 List For the second year in a row,


prochant and inc 5000 logo

Prochant is a leader in healthcare revenue cycle management

“Covid-19, Inflation, Great Resignation and rising healthcare costs are all contributing to the acceleration of ‘value migration’ in healthcare.”

Prochant has found its spot in the Inc. 5000 list of fastest growing private companies in the US. Iconic brands like Facebook, Under Armour, Microsoft, and Patagonia gained their first national exposure as honorees on the Inc. 5000. Mathew Mammen, CEO of Prochant explains why his company has advanced at a consistent Compounded Annual Growth Rate (CAGR) of over 25% in the last six years and why this second appearance on the list is no coincidence.

“Covid-19, Inflation, Great Resignation and rising healthcare costs are all contributing to the acceleration of ‘value migration’ in healthcare,” declared Mammen. “This means market share and investment are migrating from outdated business models to business designs that are better able to satisfy evolving customer priorities.

Healthcare providers who are thriving in this environment understand the importance of the right RCM partner and are prioritizing partners with technology capabilities, sustainable cost structures and enterprise level security while keeping an eye on single vendor dependencies. This has led to accelerated adoption of Prochant’s services. We are continuing to invest in Artificial Intelligence (AI) and Robotic Process Automation (RPA) technologies to raise the bar and deliver significant value to our customers.”

The companies on the 2022 Inc. 5000 have not only been successful, but have also demonstrated resilience amid supply chain woes, labor shortages, and the ongoing impact of Covid-19. Together, those companies added more than 68,394 jobs over the past three years.

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at http://www.inc.com/inc5000. The top 500 companies are featured in the September issue of Inc. magazine.

“The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work, and rising to the challenges of today.”

About Prochant, LLC

For more than 20 years, Prochant has helped HME/DME and Infusion Pharmacy providers automate and outsource their billing processes to accelerate their cash flow from insurance payers. Prochant provides solutions through an international technology and services team with domestic leadership and global resources spread across multiple US States and 4 Global Delivery Centers. Prochant is on the Inc. 5000 List of America’s fastest growing companies. It has HITRUST CSF certification, the gold standard for HIPAA. https://www.prochant.com/

More about Inc. and the Inc. 5000

Methodology

Companies on the 2022 Inc. 5000 are ranked according to percentage revenue growth from 2018 to 2021. To qualify, companies must have been founded and generating revenue by March 31, 2018. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2021. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2018 is $100,000; the minimum for 2021 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places. The top 500 companies on the Inc. 5000 are featured in Inc. magazine’s September issue. The entire Inc. 5000 can be found at http://www.inc.com/inc5000.

About Inc.

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference & Gala is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit http://www.inc.com.

For more information on the Inc. 5000 Conference & Gala, visit http://conference.inc.com/.

Share article on social media or email:

Eagle Telemedicine Extends Physician Specialist Program for Maternal Fetal Medicine


News Image

The growing physician shortage in America is having a particularly devastating impact on women in rural communities where there are much lower numbers of healthcare providers per capita.

Eagle Telemedicine, a pioneer in inpatient telemedicine, today announced that it is expanding its Maternal Fetal Medicine (Tele-MFM) telemedicine program to help address the high maternal mortality rates in rural communities. This expanded telemedicine specialty is among 15+ healthcare specialties offered by Eagle Telemedicine which delivers on-demand virtual access to physicians in 35 states.

According to recent data maternal mortality rates are on the rise in the United States, with women living in rural communities at even higher risk. Race and ethnicity also show dramatic differences in the most rural counties with Black women experiencing 59.3 deaths per 100,000 live births, compared to 19.7 for White women in the same counties. By increasing access to Maternal Fetal Medicine in rural communities, Eagle is looking to help improve maternal heath outcomes.

“The growing physician shortage in America is having a particularly devastating impact on women in rural communities where there are much lower numbers of healthcare providers per capita,” said Jason Povio, President and Chief Operating Officer, Eagle Telemedicine. “At Eagle, our mission is to deliver specialized care, anywhere. As such, we are extending our physician specialist program for Maternal Fetal Medicine for rural hospitals. We hope to help address the maternal mortality crisis in under-served communities which have traditionally not had ready access to the specialized physicians that can deliver the life-saving treatments patients need.”

Eagle Tele-MFM services complement the telemedicine company’s additional pediatric and neonatology telemedicine services, which also includes neonatal ICU (NICU) services. With demand for pediatricians expected to rise by 15% by 2026, TelePediatrics and Tele-NICU services can further improve patient outcomes in rural communities where specialist care is scarce.

Eagle Telemedicine offers technology-enabled inpatient and specialty care to address the physician shortage challenge in both rural and metropolitan communities. With 15+ physician specialties, Eagle delivers more than 75,000 patient encounters, annually, to healthcare systems and hospitals, coast-to-coast in 35 states. Offering access to telemedicine specialists, 24/7, Eagle Telemedicine reduces patient referrals, increases physician retention and enhances hospitals’ overall quality of care.

For more information on Eagle Tele-MFM services and other telemedicine specialties, visit https://www.eagletelemedicine.com/telemedicine-services/telemedicine-specialties.

About Eagle Telemedicine

Eagle Telemedicine provides technology-enabled care. Eagle was one of the first companies to emerge in the telemedicine physician service arena and is still pioneering the industry a decade later. It designs, manages and operates telemedicine programs for acute care hospitals, critical access hospitals and long-term acute care hospitals. Eagle’s solutions help facilities offer specialized care to underserved communities, eliminate locum support costs, prevent burnout, manage coverage gaps, reduce unnecessary transfers, and increase patient census. Multiple specialties include Hospitalist Medicine, Stroke and Acute Neurology, Psychiatry, Critical Care, Cardiology, Infectious Disease and a range of other specialties in a wide variety of service models. For more information, visit http://www.eagletelemedicine.com or follow us on LinkedIn at https://www.linkedin.com/company/eagle-telemedicine.

Share article on social media or email:

Project Lifesaver International Selects Clairvoyant Networks, Inc. Theora Connect™ to Quickly Locate and Rescue Individuals with Cognitive Issues Who Wander


Project Lifesaver International announced at their annual conference the addition of the Theora Connect wearable to their tracking technology solutions. For over 23 years, Project Lifesaver has been bringing loved ones home through their innovative program designed to protect, and when necessary, quickly locate individuals with cognitive disorders who are prone to the life-threatening behavior of wandering. The addition of GPS locating technology will enable Project Lifesaver’s agencies to more quickly locate wanderers and potentially avoid the time and cost of a full search and rescue.

“We had been searching for a GPS-enabled wearable for some time, but none met our high standards,” said Project Lifesaver’s CEO and Founder, Chief Gene Saunders. “The Theora Connect was the first one that can provide the reliable location and connectivity that our program demands. Another important capability was the Theora Link smartphone app for family caregivers. With this application, family members can locate their loved ones and communicate with them instantly, potentially avoiding the concern and stress of a full search and rescue.”

“Our wearable is certified on the major networks and is one of an elite group of wearables that has AT&T, TMobile and PTCRB certifications,” commented Stephen Popovich, Company President and CEO. “We are pleased to provide a pre-certified, reliable wearable for Project Lifesaver that is heads and shoulders above non-certified devices.”

Clairvoyant Networks’ wearable has been proven to reduce search and rescues. Sumter County Sheriff’s Office in Florida serves the Villages, the world’s largest retirement community. Sumter County was able to reduce the time to recover a loved one from 3 hours and 7 sheriffs to 5 minutes by having the family member locate the loved one on their smartphone application. Families report increased peace of mind because they know where their loved one is, and can instantly communicate with them. The family can recover them, without needing to call law enforcement.

In addition to GPS location and tracking and two-way hands-free voice communication at the wrist, the Theora Connect has been providing loved ones and their families with the ability to remain as independent as they can.

About Project Lifesaver International

Project Lifesaver International is a 501 (C)(3) non-profit organization that bridges the technological gap for “at-risk” populations and public safety agencies. We provide police, fire/rescue, and other first responders with a comprehensive program, including equipment and training, to quickly locate and rescue individuals with cognitive disorders who are prone to wandering, including those with Alzheimer’s disease, Autism, and Down Syndrome. The program serves the safety, security, and rescue needs of these individuals from all walks of life. They represent over 1,700 public safety agencies in all 50 states, the District of Columbia, six provinces in Canada, and Australia.

Project Lifesaver was the first organization to apply tracking technology for the search and rescue of individuals with cognitive disorders and we have remained the leader for the over 20 years. Because of their extensive experience in the search and rescue of wanderers, they have provided valuable insight and information in the development of policy and procedures for the search and safe recovery of wanderers. They, also, aid in the development of education for doctors, caregivers, school administrators, first responders, and families with loved ones at risk.

About Clairvoyant Networks, Inc.

Clairvoyant Networks, Inc. delivers situational awareness solutions to maximize the quality of life for older persons and those with chronic conditions. The Company provides a cloud platform, Theora 360™, that uses machine learning, artificial intelligence, and neural networking to collect, analyze and create actionable information. The Theora 360 platform works with clinical and non-clinical devices and can be easily integrated into enterprise applications to provide businesses with end-to-end solutions. The Company participates in ongoing research studies with government health organizations and academia to support healthier living, working, and activity for consumers, patients, and employees. Clairvoyant Networks, Inc., has offices in Austin, TX, and Raleigh, NC. For further information and to see how we can help you, please call us at 512-371-6164 or go to http://www.theoracare.com.

© 2022 Clairvoyant Networks, Inc. Theora, Theora Connect, Theora Link, and Clairvoyant Connect are trademarks or registered trademarks of Clairvoyant Networks, Inc. All other marks contained herein are the property of their respective owners.

Share article on social media or email:

HHAeXchange Expands Leadership Team to Further Support Company Growth and Momentum


News Image

We are thrilled to welcome these executives to the team as we continue to build the most comprehensive and connected homecare platform in the market.

HHAeXchange, the leading provider of homecare management solutions for payers, providers, and state Medicaid agencies, today announced it has appointed three seasoned industry experts to its leadership team. The executives are James (JC) Stanton, Chief Financial Officer; Todd Bransford, Chief Product Officer; and Nicholas Fahrney, Chief Security and Compliance Officer.

As HHAeXchange advances its ongoing commitment to building the most effective homecare ecosystem, the strategic new hires will play an instrumental role in ensuring homecare providers and payers have the tools, technologies, and resources necessary to deliver the best care. Specifically, these executives will focus on areas and operations including advancing HHAeXchange’s product innovation, data analytics capabilities, security and compliance, as well as financial reporting and processes.

The recently appointed executive team members include:


  • James (JC) Stanton – Chief Financial Officer. Stanton joins HHAeXchange with over 12 years of experience working in private equity-owned SaaS businesses. In his role at HHAeXchange, Stanton is responsible for partnering with the company on all financial reporting, budgeting and other supporting processes and controls. Stanton comes to HHAeXchange from Diligent Corporation, the global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG, where he served as VP of Finance and Operations.
  • Todd Bransford – Chief Product Officer (CPO). Bransford brings over 30 years of experience in software and SaaS-based businesses, as well as knowledge of the post-acute healthcare space. As HHAeXchange’s first CPO, Bransford is responsible for defining overall product strategy and delivery across the product portfolio. Prior to joining HHAeXchange, Bransford served as Vice President of Product Management for Fleet Solutions at Solera, delivering transportation solutions to drive compliance, safety, and productivity. He also held various leadership positions with WellSky, a health and community care technology company.
  • Nicholas Fahrney – Chief Security and Compliance Officer. Fahrney has more than 18 years of experience working in cybersecurity for multinational companies, building effective and robust information security programs. In his new role, Fahrney leads HHAeXchange’s global strategy for cybersecurity, and is responsible for the development, maintenance, and oversight of HHAeXchange’s cybersecurity and privacy programs.

“The combined leadership and expertise of Bransford, Stanton, and Fahrney reaffirm HHAeXchange’s dedication to revolutionizing homecare technology and ensuring patient safety and operational compliance,” said Greg Strobel, CEO of HHAeXchange. “We are thrilled to welcome these executives to the team as we continue to build the most comprehensive and connected homecare platform in the market.”

To learn more about HHAeXchange and its leadership team, visit hhaexchange.com. Additional information on career opportunities and open positions can be found at hhaexchange.com/careers.

About HHAeXchange

Founded in 2008, HHAeXchange is the leading technology platform for homecare and self-direction program management. Developed specifically for Medicaid home and community-based services (HCBS), HHAeXchange connects state agencies, managed care payers, providers, and caregivers through its intuitive web-based platform, enabling unparalleled communication, transparency, efficiency, and compliance. For more information, visit hhaexchange.com or follow the company on Twitter, LinkedIn and Facebook.

Share article on social media or email:



The Impact of a Rapid Blood Culture Identification System on a Pediatric Institution, Upcoming Webinar Hosted by Xtalks


Pediatric blood cultures present unique problems such as fastidious organisms, antimicrobial treatment and small specimen volumes.

Although automated blood systems can save time, subcultures are required for growth of the organism, specific biochemical testing, assays for the identification of potential pathogens and antimicrobial susceptibility testing. Pediatric blood cultures present unique problems such as fastidious organisms, antimicrobial treatment and small specimen volumes. Furthermore, contamination of blood cultures by skin microbiota such as coagulase-negative Staphylococci may be problematic in specific populations such as immunocompromised patients where determining true pathogens can be more difficult.

GenMark’s ePlex® System is a molecular amplification and identification system with three panels for the identification of organisms causing bloodstream infections and certain associated antibiotic resistance genes. To aid in reducing the time to identification of key pathogens, resistances and possible contaminants, the ePlex® Blood Culture Identification (BCID) Panels are fully automated sample-to-answer PCR-based assays designed to identify gram-positive and gram-negative bacteria, fungi and bacterial resistance genes in approximately 90 minutes from positive blood culture.

Join the featured speaker to explore how a rapid blood culture identification system can be utilized in a pediatric population while navigating best practices for integration of the system into a hospital, laboratory and stewardship network.

Join Joel E. Mortensen, PhD, Director of the Diagnostic Infectious Diseases Testing Laboratories, Cincinnati Children’s Hospital, for the live webinar on Friday, September 23, 2022, at 12pm EDT (9am PDT).

For more information, or to register for this event, visit The Impact of a Rapid Blood Culture Identification System on a Pediatric Institution.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Site, Advocate and Technology Insights, Upcoming Webinar Hosted by Xtalks


Join this webinar to hear key perspectives from a distinguished panel of experts in rare disease, rare disease clinical trials and diversity.

Rare disease clinical trials are challenging on many levels, from identifying eligible patients, to making it convenient for caregivers, to the outsized expense (over $300k per patient) compared to other therapeutic areas. Not to mention that, in many cases, families are looking to clinical trials as their last, best, or only hope for treatment or a cure — when in reality, clinical trials are more likely to benefit families down the line.

Join this webinar to hear key perspectives from a distinguished panel of experts in rare disease, rare disease clinical trials and diversity.

Featured speaker Daniel Defabio will share the realities of rare disease families — the expectations and hope, frustrations and challenges and importance of maintaining a positive outlook — of participating in rare disease trials.

Featured speaker Dr. Fabian Sandoval will focus on driving diversity in clinical trials — something that is already a patient recruitment challenge without the intersection of rare disease. But diverse patient populations get rare diseases too — so what can be done to serve this community.

Featured speaker Andrea Valente will share trends and solutions that consider the participant experience just as important as the data captured during a trial, and how study sponsors and sites can get the most out of them in 2022 and beyond.

Join Daniel Defabio, Co-Founder and Co-Producer, DISORDER: The Rare Disease Film Festival, Director of Community Engagement, Global Genes; Fabian Sandoval, MD, President & CEO, Emerson Clinical Research Institute; and Andrea Valente, CEO, ClinOne, for the live webinar on Tuesday, September 20, 2022, at 12pm EDT (5pm BST/UK).

For more information, or to register for this event, visit Rare Disease Clinical Trials: Site, Advocate and Technology Insights.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

InVivo Biosystems and Thaena Announce Novel Metabolite Research Platform With Compelling Longevity and Healthspan Implications and Outcomes


“We are investigating a novel approach to looking at the metabolites or postbiotics that the human microbiota produces. The mixture surprised us when it significantly extended lifespan and healthspan,” said Andrea McBeth, co-founder of Thaena.

InVivo Biosystems, experts in preclinical in vivo testing and CRISPR genome editing, and Thaena Inc., a science-based wellness company developing novel microbiome-based therapies, today announced measurably superior healthspan and lifespan results from research (1) on ThaenaBiotic™ powder, a sterilized postbiotic mixture derived from healthy human stool. The mix of compounds significantly improved both lifespan and healthspan in Caenorhabditis elegans, the latter outperforming both Resveratrol and Rapamycin control groups when tested on the InVivo Vitality Platform.

“We are investigating a novel approach to looking at the metabolites or postbiotics that the human microbiota produces. The mixture surprised us when it significantly extended lifespan and healthspan,” said Andrea McBeth, co-founder of Thaena. “Over the past decade, fecal transplant use in clinical trials has challenged our understanding of the role the microbiome plays in immune, neurologic, and metabolic health. We’ve learned that not only does the composition of the microbiome matter from a species-viewpoint, but also what it produces. The InVivo Vitality Platform provided a new and more cost-effective way to investigate how such a complex mixture of small molecules produced by the microbiome could impact longevity and healthspan. We are incredibly excited by these findings and believe this will open a new world of discovery for longevity innovation.”

The study, undertaken by InVivo Biosystems on behalf of Thaena, utilizes C. elegans as the scientifically standard model organism that has contributed to the discovery of many compounds with potential life- and healthspan extending benefits. The short lifespan of these animals, paired with the ability to determine whether genetic pathways such as mTOR or insulin signaling are involved, make them a powerful tool for studying longevity effects. Treatment with ThaenaBiotic protected the animals from the effects of oxidizing chemicals better than Vitamin C and cause the animals to continue healthy movement patterns in late life. The two companies are now undertaking a transcriptomics study to determine the role of the underlying genetics in creating these health benefits, also known as the mechanism of action.

Kat McCormick, PhD., vice president of Product at InVivo Biosystems, added, “We, along with Thaena, didn’t expect to see these findings and are excited to move forward together to expand research into how and why this treatment affects longevity. We are excited that our scientific services enable growth and product development for new companies like Thaena that will fuel new options and innovation in the health and wellness space. It really is a cutting edge, novel scientific approach to looking at how gut health and longevity are interrelated and a cost-effective way for Thaena to deliver scientifically proven wellness products to the market.”

The age-tech and longevity industry is one of the fastest growing segments and has expanded into a massive marketplace serving an aging population of baby boomers. In 2021, the global anti-aging market was estimated to be worth $60.42 billion. It is expected to be worth around $119.6 billion by 2030 and growing at a compound annual growth rate (CAGR) of 7.9 percent from 2022 to 2030. (2)

The InVivo Efficacy Evaluation Platform

The InVivo Efficacy Evaluation Platform can quickly and economically test a compound or a formulation’s ability to impact the genes and hallmarks of good health with large sample sizes of live animals in less than four months. Scientific testing via the InVivo Vitality Platform helps the industry deliver confirmation of specific benefits as well as assist companies in developing these products. The platform uses automated scanning to produce smooth, high-resolution survival curves and to help ensure reproducibility, detection power, and robust conclusions.

The InVivo Efficacy Evaluation Platform offers the following studies:


  • Genetic Signature Study: determine how a compound or formulation affects gene expression using RNAseq and transcriptomics technology. Data Delivered as quickly as three months.
  • Vitality Study: perform lifetime monitoring of a large population of animals to determine whether compounds and formulations affect lifespan and healthspan. Data Delivered as quickly as four months.
  • Antioxidant Capacity Study: uncover whether a compound or formulation has antioxidant properties using a standardized reactive oxygen species exposure assay. Data Delivered as quickly as two months.
  • Mitochondrial Function Study: investigate the impact of a compound or formulation on mitochondrial function across the lifespan. Data Delivered as quickly as four months.

# # #

1. Research Report: https://invivobiosystems.com/wp-content/uploads/2022/08/Thaena-Final-Report_Aug2022.pdf or https://www.thaena.com/science 2. Source: Precedence Research

InVivo Biosystems Founded in Eugene, InVivo Biosystems provides end-to-end services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. The company’s mission is to build the world’s most effective genetic animal models to advance human health. An expert in zebrafish and C. elegans models, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging and other disease studies. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies that need to quickly make go/no-go decisions in the early-stage development of new compounds. For more information, visit http://www.invivobiosystems.com or the company’s blog: InVivo Insights.

Thaena

A female-founded wellness company based in Portland, Ore. that is dedicated to balancing the microbial ecosystems by leveraging the potential of the human microbiome. The Thaena Team is working to develop evidence-based microbiome-related products and an educational platform supported by the most up-to-date research. The company is pioneering an innovative method for processing human stool that maintains a complex mixture of whole biome molecules (postbiotics) that represent the entirety of a healthy person’s gut ecosystem. Thaena’s first product, ThaenaBioticTM, is the first-of-its-kind whole biome-derived dietary supplement composed entirely of postbiotic molecules. For more information, visit http://www.thaena.com.

For More Information:

Wenlan Hu, VP of Marketing Andrea McBeth, Co-founder

InVivo Biosystems Thaena Inc.

541-206-8430 503-506-8732

wenlan.hu@invivobiosystems.com andrea@thaena.com

Share article on social media or email:

Inventor Is Awarded a US Patent for a New Version of Tic Tac Toe


James Porter, Author, CEO of StressStop and Inventor of TipTacToe

Mindfulness meets gameplay.

Inventor Patents a New Way to Play Tic Tac Toe

James Porter, of Norwalk, CT, has invented a brand-new way to play Tic Tac Toe and The United States Patent and Trademark Office has recognized Porter’s unique game board design by awarding him a US government patent. “We’ve turned the game of Tic Tac Toe upside down,” Porter explains.

Using blocks marked with X’s and O’s, players put their pieces into a grid with the letter side facing down. As soon as they make a move, any evidence of it disappears. (See video) Porter, author of books and other materials on mindfulness, says he wanted to create a game that encourages people to be more mindful.

“If you don’t pay careful attention to where you and your opponent place each block, you will lose,” Porter said. He calls his new game Tip Tac Toe™, because at the end of play you have to TIP the box over to see who has won. “The unique design of the box is what allowed us to obtain a patent.” The USPTO also awarded him a trademark for the name Tip Tac Toe™.

“The problem with regular Tic Tac Toe is that far too often the game ends in a draw. Tip Tac Toe™ is much more challenging because we’ve added one very important rule: If you pull out a lettered block that’s already been inserted into the grid – whether it’s yours or your opponent’s – you lose.”

“And if the game should end in a draw,” Porter explains, “each player must withdraw his or her own blocks, one by one. This always adds a bit of drama to the game and further diminishes the chances of it ending in a draw.”

Now that he has been awarded a patent, Porter is looking for a distributor to take over the manufacture and marketing of the game. In addition, he will soon be launching a Kickstarter campaign, so he can manufacture a limited edition of the game himself. “I want to create a high-quality wooden version of the game that a user can proudly display on their coffee table.” Porter says board game enthusiasts can learn more about the Kickstarter campaign at TipTacToe.net.

Porter, who is CEO of the stress management and mindfulness company he founded, StressStop, says his game is appropriate for all ages. “There’s an easy way of playing the game that’s perfect for kids, and a harder way of playing the game which is much more challenging. Even seniors can get a good mental workout from playing an intermediate level version of this same game.”

Contact information

James Porter, Inventor

Jim@stressstop.com

Phone: 203 856 8256

Share article on social media or email:

Todd O. Davis, former President/GM of Zimmer Biomet, joins Maxx Orthopedics as strategic advisor to further its ASC offering


News Image

“QRS is exactly what today’s orthopedic customer is looking for and will be particularly attractive to the growing ASC market.,” Todd observed.

Maxx Orthopedics, Inc. announced today that they have entered into an advisory relationship with Mr. Todd O. Davis, who will work with senior leadership to advance the company’s ambulatory surgery center (ASC) business in the US by expanding its footprint commercially as well as organizationally.

Todd Davis comes with a wealth of experience in the ever-changing world of orthopedics with over 30 years focused on total joint replacement products and served as president and general manager of the global knee business for Zimmer Biomet. After leaving Zimmer Biomet in July 2019, as President and General Manager, Todd recognized a need within the industry to offer the strategic orchestration that allows orthopedic companies to create constructive and progressive disruption in the competitive marketplace. ​Todd sees that opportunity with Maxx Orthopedics given their robust product portfolio in hip and knee, combined with the truly differentiated Quick Recovery System, QRS. “QRS is exactly what today’s orthopedic customer is looking for and will be particularly attractive to the growing ASC market.,” Todd observed.

Maxx Orthopedics is focused on advancing its growth strategy in the US through continuing investment in QRS, innovative portfolio expansion and associated organizational expansion. Ashesh Shah, CEO of Maxx Orthopedics, states “Todd’s drive, expertise and experience will be extremely valuable to help propel our business forward. We expect his relationship network will help expand our presence throughout the US and look forward to working with him.”

About Maxx Orthopedics

Maxx Orthopedics is the manufacturer of the Freedom Knee® System, Libertas® Total Hip System and Quick Recovery Solutions (QRS®). The company develops and markets innovative orthopedic medical devices worldwide with a focus on providing state-of-the-art implants and related solutions that best restore patient mobility while accommodating lifestyle, anatomical and economic needs. Maxx Medical, Pvt. Ltd., is the parent company of Maxx Orthopedics, Inc. Find out more at http://www.maxxortho.com

Share article on social media or email: